Review



fluorogenic substrate mca-pro-leu-gly-leu-dpa-ala-arg-nh 2 ·tfa  (Merck KGaA)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Merck KGaA fluorogenic substrate mca-pro-leu-gly-leu-dpa-ala-arg-nh 2 ·tfa
    Fluorogenic Substrate Mca Pro Leu Gly Leu Dpa Ala Arg Nh 2 ·Tfa, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pro+fluorogenic+substrate/fluorogenic+substrate+mca+pro+leu+gly+leu+dpa+ala+arg+nh+2+%C2%B7tfa/pmc11416218-403-29-46
    Average 90 stars, based on 1 article reviews
    fluorogenic substrate mca-pro-leu-gly-leu-dpa-ala-arg-nh 2 ·tfa - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    Activity Assay:

    Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions
    Article Snippet: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA , Merck Millipore , BML-P276-0001.

    Article Title: Quantitative Mapping of Binding Specificity Landscapes for Homologous Targets by using a High-Throughput Method
    Article Snippet: Bands were visualized by staining with Instant Blue (CBS Scientific, CA, USA).

    Article Title: Potent inhibition of MMP-9 by a novel sustained-release platform attenuates left ventricular remodeling following myocardial infarction.
    Article Snippet: Sustained drug-release systems prolong the retention of therapeutic drugs within target tissues to alleviate the need for repeated drug administration.. Two major caveats of the current systems are that the release rate and the timing cannot be predicted or fine-tuned because they rely on uncontrolled environmental conditions and that the system must be redesigned for each drug and treatment regime because the drug is bound via interactions that are specific to its structure and composition.. We present a controlled and universal sustained drug-release system, which comprises minute spherical particles in which a therapeutic protein is affinity-bound to alginate sulfate (AlgS) through one or more short heparin-binding peptide (HBP) sequence repeats.

    Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy
    Article Snippet: The inhibition of the catalytic activity of MMP9 (0.325 nM) against the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA (7.5 μM, Merck Millipore) was determined using N-TIMP2 WT at 0.0625–1 nM, C9 at 0.031–1 nM, and C9-PEX at 0.047–1 nM.

    Article Title: Targeting the MMP-14/MMP-2/integrin α v β 3 axis with multispecific N-TIMP2–based antagonists for cancer therapy
    Article Snippet: The dissociation of each complex in IBB without BSA was monitored for 600 s. MMP-14 CAT inhibition studies The K m value for the purified MMP-14 CAT protein was determined by measuring MMP-14 CAT activity against different concentrations (0–25 μ m ) of the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA (Merck Millipore) and fitting the data to the Michaelis-Menten equation ( Equation 1 ) using Prism (GraphPad Software).

    Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy
    Article Snippet: The inhibition of the catalytic activity of MMP9 (0.325 nM) against the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2·TFA (7.5 mM, Merck Millipore) was determined using N-TIMP2WT at 0.0625–1 nM, C9 at 0.031–1 nM, and C9-PEX at 0.047–1 nM.

    Article Title: Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition.
    Article Snippet: Tissue inhibitors of metalloproteinases (TIMPs) are natural inhibitors of the matrix metalloproteinase (MMP) family of proteins, whose members are key regulators of the proteolysis of extracellular matrix components and hence of multiple biological processes.. In particular, imbalanced activity of matrix metalloproteinase-14 (MMP-14) may lead to the development of cancer and cardiovascular and other diseases.. This study aimed to engineer TIMP2, one of the four homologous TIMPs, as a potential therapeutic by virtue of its ability to bind to the active-site Zn of MMP-14.

    Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions
    Article Snippet: The catalytic activity ( K m value) of the purified MMP9 CAT enzyme was determined by measuring 0.5 nM MMP9 CAT activity against different concentrations (0–50 μM) of the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA [where Mca is (7-methoxycoumarin-4-yl)acetyl, Dpa is N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl and TFA is trifluoroacetic acid)] (Merck Millipore, CA, USA) in TCNB buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM CaCl 2 , and 0.05% Brij).

    Purification:

    Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions
    Article Snippet: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA , Merck Millipore , BML-P276-0001.

    Article Title: Quantitative Mapping of Binding Specificity Landscapes for Homologous Targets by using a High-Throughput Method
    Article Snippet: Bands were visualized by staining with Instant Blue (CBS Scientific, CA, USA).

    Article Title: Potent inhibition of MMP-9 by a novel sustained-release platform attenuates left ventricular remodeling following myocardial infarction.
    Article Snippet: Sustained drug-release systems prolong the retention of therapeutic drugs within target tissues to alleviate the need for repeated drug administration.. Two major caveats of the current systems are that the release rate and the timing cannot be predicted or fine-tuned because they rely on uncontrolled environmental conditions and that the system must be redesigned for each drug and treatment regime because the drug is bound via interactions that are specific to its structure and composition.. We present a controlled and universal sustained drug-release system, which comprises minute spherical particles in which a therapeutic protein is affinity-bound to alginate sulfate (AlgS) through one or more short heparin-binding peptide (HBP) sequence repeats.

    Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy
    Article Snippet: The inhibition of the catalytic activity of MMP9 (0.325 nM) against the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA (7.5 μM, Merck Millipore) was determined using N-TIMP2 WT at 0.0625–1 nM, C9 at 0.031–1 nM, and C9-PEX at 0.047–1 nM.

    Article Title: Targeting the MMP-14/MMP-2/integrin α v β 3 axis with multispecific N-TIMP2–based antagonists for cancer therapy
    Article Snippet: The dissociation of each complex in IBB without BSA was monitored for 600 s. MMP-14 CAT inhibition studies The K m value for the purified MMP-14 CAT protein was determined by measuring MMP-14 CAT activity against different concentrations (0–25 μ m ) of the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA (Merck Millipore) and fitting the data to the Michaelis-Menten equation ( Equation 1 ) using Prism (GraphPad Software).

    Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy
    Article Snippet: The inhibition of the catalytic activity of MMP9 (0.325 nM) against the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2·TFA (7.5 mM, Merck Millipore) was determined using N-TIMP2WT at 0.0625–1 nM, C9 at 0.031–1 nM, and C9-PEX at 0.047–1 nM.

    Article Title: Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition.
    Article Snippet: Tissue inhibitors of metalloproteinases (TIMPs) are natural inhibitors of the matrix metalloproteinase (MMP) family of proteins, whose members are key regulators of the proteolysis of extracellular matrix components and hence of multiple biological processes.. In particular, imbalanced activity of matrix metalloproteinase-14 (MMP-14) may lead to the development of cancer and cardiovascular and other diseases.. This study aimed to engineer TIMP2, one of the four homologous TIMPs, as a potential therapeutic by virtue of its ability to bind to the active-site Zn of MMP-14.

    Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions
    Article Snippet: The catalytic activity ( K m value) of the purified MMP9 CAT enzyme was determined by measuring 0.5 nM MMP9 CAT activity against different concentrations (0–50 μM) of the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA [where Mca is (7-methoxycoumarin-4-yl)acetyl, Dpa is N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl and TFA is trifluoroacetic acid)] (Merck Millipore, CA, USA) in TCNB buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM CaCl 2 , and 0.05% Brij).

    Concentration Assay:

    Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions
    Article Snippet: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA , Merck Millipore , BML-P276-0001.

    Article Title: Quantitative Mapping of Binding Specificity Landscapes for Homologous Targets by using a High-Throughput Method
    Article Snippet: Bands were visualized by staining with Instant Blue (CBS Scientific, CA, USA).

    Article Title: Potent inhibition of MMP-9 by a novel sustained-release platform attenuates left ventricular remodeling following myocardial infarction.
    Article Snippet: Sustained drug-release systems prolong the retention of therapeutic drugs within target tissues to alleviate the need for repeated drug administration.. Two major caveats of the current systems are that the release rate and the timing cannot be predicted or fine-tuned because they rely on uncontrolled environmental conditions and that the system must be redesigned for each drug and treatment regime because the drug is bound via interactions that are specific to its structure and composition.. We present a controlled and universal sustained drug-release system, which comprises minute spherical particles in which a therapeutic protein is affinity-bound to alginate sulfate (AlgS) through one or more short heparin-binding peptide (HBP) sequence repeats.

    Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy
    Article Snippet: The inhibition of the catalytic activity of MMP9 (0.325 nM) against the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA (7.5 μM, Merck Millipore) was determined using N-TIMP2 WT at 0.0625–1 nM, C9 at 0.031–1 nM, and C9-PEX at 0.047–1 nM.

    Article Title: Targeting the MMP-14/MMP-2/integrin α v β 3 axis with multispecific N-TIMP2–based antagonists for cancer therapy
    Article Snippet: The dissociation of each complex in IBB without BSA was monitored for 600 s. MMP-14 CAT inhibition studies The K m value for the purified MMP-14 CAT protein was determined by measuring MMP-14 CAT activity against different concentrations (0–25 μ m ) of the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA (Merck Millipore) and fitting the data to the Michaelis-Menten equation ( Equation 1 ) using Prism (GraphPad Software).

    Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy
    Article Snippet: The inhibition of the catalytic activity of MMP9 (0.325 nM) against the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2·TFA (7.5 mM, Merck Millipore) was determined using N-TIMP2WT at 0.0625–1 nM, C9 at 0.031–1 nM, and C9-PEX at 0.047–1 nM.

    Article Title: Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition.
    Article Snippet: Tissue inhibitors of metalloproteinases (TIMPs) are natural inhibitors of the matrix metalloproteinase (MMP) family of proteins, whose members are key regulators of the proteolysis of extracellular matrix components and hence of multiple biological processes.. In particular, imbalanced activity of matrix metalloproteinase-14 (MMP-14) may lead to the development of cancer and cardiovascular and other diseases.. This study aimed to engineer TIMP2, one of the four homologous TIMPs, as a potential therapeutic by virtue of its ability to bind to the active-site Zn of MMP-14.

    Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions
    Article Snippet: The catalytic activity ( K m value) of the purified MMP9 CAT enzyme was determined by measuring 0.5 nM MMP9 CAT activity against different concentrations (0–50 μM) of the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA [where Mca is (7-methoxycoumarin-4-yl)acetyl, Dpa is N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl and TFA is trifluoroacetic acid)] (Merck Millipore, CA, USA) in TCNB buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM CaCl 2 , and 0.05% Brij).

    Inhibition:

    Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions
    Article Snippet: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA , Merck Millipore , BML-P276-0001.

    Article Title: Quantitative Mapping of Binding Specificity Landscapes for Homologous Targets by using a High-Throughput Method
    Article Snippet: Bands were visualized by staining with Instant Blue (CBS Scientific, CA, USA).

    Article Title: Potent inhibition of MMP-9 by a novel sustained-release platform attenuates left ventricular remodeling following myocardial infarction.
    Article Snippet: Sustained drug-release systems prolong the retention of therapeutic drugs within target tissues to alleviate the need for repeated drug administration.. Two major caveats of the current systems are that the release rate and the timing cannot be predicted or fine-tuned because they rely on uncontrolled environmental conditions and that the system must be redesigned for each drug and treatment regime because the drug is bound via interactions that are specific to its structure and composition.. We present a controlled and universal sustained drug-release system, which comprises minute spherical particles in which a therapeutic protein is affinity-bound to alginate sulfate (AlgS) through one or more short heparin-binding peptide (HBP) sequence repeats.

    Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy
    Article Snippet: The inhibition of the catalytic activity of MMP9 (0.325 nM) against the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA (7.5 μM, Merck Millipore) was determined using N-TIMP2 WT at 0.0625–1 nM, C9 at 0.031–1 nM, and C9-PEX at 0.047–1 nM.

    Article Title: Targeting the MMP-14/MMP-2/integrin α v β 3 axis with multispecific N-TIMP2–based antagonists for cancer therapy
    Article Snippet: The dissociation of each complex in IBB without BSA was monitored for 600 s. MMP-14 CAT inhibition studies The K m value for the purified MMP-14 CAT protein was determined by measuring MMP-14 CAT activity against different concentrations (0–25 μ m ) of the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA (Merck Millipore) and fitting the data to the Michaelis-Menten equation ( Equation 1 ) using Prism (GraphPad Software).

    Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy
    Article Snippet: The inhibition of the catalytic activity of MMP9 (0.325 nM) against the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2·TFA (7.5 mM, Merck Millipore) was determined using N-TIMP2WT at 0.0625–1 nM, C9 at 0.031–1 nM, and C9-PEX at 0.047–1 nM.

    Article Title: Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition.
    Article Snippet: Tissue inhibitors of metalloproteinases (TIMPs) are natural inhibitors of the matrix metalloproteinase (MMP) family of proteins, whose members are key regulators of the proteolysis of extracellular matrix components and hence of multiple biological processes.. In particular, imbalanced activity of matrix metalloproteinase-14 (MMP-14) may lead to the development of cancer and cardiovascular and other diseases.. This study aimed to engineer TIMP2, one of the four homologous TIMPs, as a potential therapeutic by virtue of its ability to bind to the active-site Zn of MMP-14.

    Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions
    Article Snippet: The catalytic activity ( K m value) of the purified MMP9 CAT enzyme was determined by measuring 0.5 nM MMP9 CAT activity against different concentrations (0–50 μM) of the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA [where Mca is (7-methoxycoumarin-4-yl)acetyl, Dpa is N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl and TFA is trifluoroacetic acid)] (Merck Millipore, CA, USA) in TCNB buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM CaCl 2 , and 0.05% Brij).

    Fluorescence:

    Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions
    Article Snippet: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA , Merck Millipore , BML-P276-0001.

    Article Title: Quantitative Mapping of Binding Specificity Landscapes for Homologous Targets by using a High-Throughput Method
    Article Snippet: Bands were visualized by staining with Instant Blue (CBS Scientific, CA, USA).

    Article Title: Potent inhibition of MMP-9 by a novel sustained-release platform attenuates left ventricular remodeling following myocardial infarction.
    Article Snippet: Sustained drug-release systems prolong the retention of therapeutic drugs within target tissues to alleviate the need for repeated drug administration.. Two major caveats of the current systems are that the release rate and the timing cannot be predicted or fine-tuned because they rely on uncontrolled environmental conditions and that the system must be redesigned for each drug and treatment regime because the drug is bound via interactions that are specific to its structure and composition.. We present a controlled and universal sustained drug-release system, which comprises minute spherical particles in which a therapeutic protein is affinity-bound to alginate sulfate (AlgS) through one or more short heparin-binding peptide (HBP) sequence repeats.

    Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy
    Article Snippet: The inhibition of the catalytic activity of MMP9 (0.325 nM) against the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA (7.5 μM, Merck Millipore) was determined using N-TIMP2 WT at 0.0625–1 nM, C9 at 0.031–1 nM, and C9-PEX at 0.047–1 nM.

    Article Title: Targeting the MMP-14/MMP-2/integrin α v β 3 axis with multispecific N-TIMP2–based antagonists for cancer therapy
    Article Snippet: The dissociation of each complex in IBB without BSA was monitored for 600 s. MMP-14 CAT inhibition studies The K m value for the purified MMP-14 CAT protein was determined by measuring MMP-14 CAT activity against different concentrations (0–25 μ m ) of the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA (Merck Millipore) and fitting the data to the Michaelis-Menten equation ( Equation 1 ) using Prism (GraphPad Software).

    Article Title: Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy
    Article Snippet: The inhibition of the catalytic activity of MMP9 (0.325 nM) against the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2·TFA (7.5 mM, Merck Millipore) was determined using N-TIMP2WT at 0.0625–1 nM, C9 at 0.031–1 nM, and C9-PEX at 0.047–1 nM.

    Article Title: Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition.
    Article Snippet: Tissue inhibitors of metalloproteinases (TIMPs) are natural inhibitors of the matrix metalloproteinase (MMP) family of proteins, whose members are key regulators of the proteolysis of extracellular matrix components and hence of multiple biological processes.. In particular, imbalanced activity of matrix metalloproteinase-14 (MMP-14) may lead to the development of cancer and cardiovascular and other diseases.. This study aimed to engineer TIMP2, one of the four homologous TIMPs, as a potential therapeutic by virtue of its ability to bind to the active-site Zn of MMP-14.

    Article Title: Deep neural networks for predicting the affinity landscape of protein-protein interactions
    Article Snippet: The catalytic activity ( K m value) of the purified MMP9 CAT enzyme was determined by measuring 0.5 nM MMP9 CAT activity against different concentrations (0–50 μM) of the fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 ·TFA [where Mca is (7-methoxycoumarin-4-yl)acetyl, Dpa is N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl and TFA is trifluoroacetic acid)] (Merck Millipore, CA, USA) in TCNB buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM CaCl 2 , and 0.05% Brij).



    Similar Products

    94
    MedChemExpress fluorogenic substrate z fr afc
    Fluorogenic Substrate Z Fr Afc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pro+fluorogenic+substrate/Z-Gly-Pro-Arg-AMC+hydrochloride/pmc13399510-89-18-23
    Average 94 stars, based on 1 article reviews
    fluorogenic substrate z fr afc - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    MedChemExpress fluorogenic substrate mca ala pro lys dnp oh
    Fluorogenic Substrate Mca Ala Pro Lys Dnp Oh, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pro+fluorogenic+substrate/Mca-Ala-Pro-Lys(Dnp)-OH/pmc13071878-405-14-18
    Average 93 stars, based on 1 article reviews
    fluorogenic substrate mca ala pro lys dnp oh - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    MedChemExpress fluorogenic substrate mcaala pro lys dnp oh
    Fluorogenic Substrate Mcaala Pro Lys Dnp Oh, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pro+fluorogenic+substrate/Mca-Ala-Pro-Lys(Dnp)-OH/pm41875055-415-14-17
    Average 93 stars, based on 1 article reviews
    fluorogenic substrate mcaala pro lys dnp oh - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    R&D Systems fluorogenic tripeptide substrate h met gly proamc
    Fluorogenic Tripeptide Substrate H Met Gly Proamc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pro+fluorogenic+substrate/H-Met-Gly-Pro-AMC+Fluorogenic+Peptide+Substrate/pm41239757-64-10-18
    Average 94 stars, based on 1 article reviews
    fluorogenic tripeptide substrate h met gly proamc - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    R&D Systems fluorogenic tripeptide substrate h met gly pro amc
    Enzyme activity profiles of DPPIV family proteases. (A) To compare the peptidase activities of hDPP4, hDPP9, C. elegans DPF‐3, and the catalytic mutant DPF‐3 (S784A), the <t>fluorogenic</t> <t>tripeptide</t> <t>substrate</t> <t>H‐Met‐Gly‐Pro‐AMC</t> was used over a range of concentrations (0.5–64 μ m ). hDPP4 displayed robust, concentration‐dependent activity, reaching 100% normalized fluorescence at 64 μ m substrate. In contrast, wild‐type DPF‐3 showed substantially lower activity, achieving only ~25% of the maximal signal at the highest substrate concentration. hDPP9 activity was negligible under these conditions, and the S784A mutation abrogated DPF‐3 activity completely, confirming loss of catalytic function. (B, C) Michaelis–Menten analysis of DPF‐3 (B) and hDPP4 (C) revealed distinct kinetic parameters. Nonlinear regression yielded for DPF‐3 a V max of 33 193 AU min −1 and a K m of 245.6 μ m . hDPP4 exhibited a higher catalytic efficiency, with V max = 56 027 AU min −1 and K m = 461.5 μ m . The higher V max of hDPP4, despite its higher K m , underscores its greater turnover capacity on this substrate. (D, E) Dose–response curves for the hDPP8/9 inhibitor 1G244 and the hDPP4 inhibitor vildagliptin were generated against DPF‐3 and hDPP4 using substrate concentrations near each enzyme's K m . For DPF‐3, 1G244 inhibited activity with an IC 50 = 499.5 n m , whereas vildagliptin was more potent (IC 50 = 142.1 n m ) (D). DPP4 was more sensitive to both 1G244 (IC 50 = 43.3 n m ) and vildagliptin (IC 50 = 14.8 n m ) (E), indicating differential inhibitor specificities within the DPPIV family. Each graph represents the mean data from triplicate experiments, and the error bars represent the standard deviation.
    Fluorogenic Tripeptide Substrate H Met Gly Pro Amc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pro+fluorogenic+substrate/H-Met-Gly-Pro-AMC+Fluorogenic+Peptide+Substrate/pmc12883895-58-10-18
    Average 94 stars, based on 1 article reviews
    fluorogenic tripeptide substrate h met gly pro amc - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    86
    Ambeed Inc fluorogenic peptide substrate mca lys pro leu gly leu dap dnp ala arg nh2
    Enzyme activity profiles of DPPIV family proteases. (A) To compare the peptidase activities of hDPP4, hDPP9, C. elegans DPF‐3, and the catalytic mutant DPF‐3 (S784A), the <t>fluorogenic</t> <t>tripeptide</t> <t>substrate</t> <t>H‐Met‐Gly‐Pro‐AMC</t> was used over a range of concentrations (0.5–64 μ m ). hDPP4 displayed robust, concentration‐dependent activity, reaching 100% normalized fluorescence at 64 μ m substrate. In contrast, wild‐type DPF‐3 showed substantially lower activity, achieving only ~25% of the maximal signal at the highest substrate concentration. hDPP9 activity was negligible under these conditions, and the S784A mutation abrogated DPF‐3 activity completely, confirming loss of catalytic function. (B, C) Michaelis–Menten analysis of DPF‐3 (B) and hDPP4 (C) revealed distinct kinetic parameters. Nonlinear regression yielded for DPF‐3 a V max of 33 193 AU min −1 and a K m of 245.6 μ m . hDPP4 exhibited a higher catalytic efficiency, with V max = 56 027 AU min −1 and K m = 461.5 μ m . The higher V max of hDPP4, despite its higher K m , underscores its greater turnover capacity on this substrate. (D, E) Dose–response curves for the hDPP8/9 inhibitor 1G244 and the hDPP4 inhibitor vildagliptin were generated against DPF‐3 and hDPP4 using substrate concentrations near each enzyme's K m . For DPF‐3, 1G244 inhibited activity with an IC 50 = 499.5 n m , whereas vildagliptin was more potent (IC 50 = 142.1 n m ) (D). DPP4 was more sensitive to both 1G244 (IC 50 = 43.3 n m ) and vildagliptin (IC 50 = 14.8 n m ) (E), indicating differential inhibitor specificities within the DPPIV family. Each graph represents the mean data from triplicate experiments, and the error bars represent the standard deviation.
    Fluorogenic Peptide Substrate Mca Lys Pro Leu Gly Leu Dap Dnp Ala Arg Nh2, supplied by Ambeed Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pro+fluorogenic+substrate/ala+arg+dap+dnp+fluorogenic+gly+leu+leu+lys+mca+nh2+peptide+pro+substrate/pm41101741-55-8-19
    Average 86 stars, based on 1 article reviews
    fluorogenic peptide substrate mca lys pro leu gly leu dap dnp ala arg nh2 - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    94
    R&D Systems h met gly pro 7 amino 4 methylcoumarin hydrochloride
    Enzyme activity profiles of DPPIV family proteases. (A) To compare the peptidase activities of hDPP4, hDPP9, C. elegans DPF‐3, and the catalytic mutant DPF‐3 (S784A), the <t>fluorogenic</t> <t>tripeptide</t> <t>substrate</t> <t>H‐Met‐Gly‐Pro‐AMC</t> was used over a range of concentrations (0.5–64 μ m ). hDPP4 displayed robust, concentration‐dependent activity, reaching 100% normalized fluorescence at 64 μ m substrate. In contrast, wild‐type DPF‐3 showed substantially lower activity, achieving only ~25% of the maximal signal at the highest substrate concentration. hDPP9 activity was negligible under these conditions, and the S784A mutation abrogated DPF‐3 activity completely, confirming loss of catalytic function. (B, C) Michaelis–Menten analysis of DPF‐3 (B) and hDPP4 (C) revealed distinct kinetic parameters. Nonlinear regression yielded for DPF‐3 a V max of 33 193 AU min −1 and a K m of 245.6 μ m . hDPP4 exhibited a higher catalytic efficiency, with V max = 56 027 AU min −1 and K m = 461.5 μ m . The higher V max of hDPP4, despite its higher K m , underscores its greater turnover capacity on this substrate. (D, E) Dose–response curves for the hDPP8/9 inhibitor 1G244 and the hDPP4 inhibitor vildagliptin were generated against DPF‐3 and hDPP4 using substrate concentrations near each enzyme's K m . For DPF‐3, 1G244 inhibited activity with an IC 50 = 499.5 n m , whereas vildagliptin was more potent (IC 50 = 142.1 n m ) (D). DPP4 was more sensitive to both 1G244 (IC 50 = 43.3 n m ) and vildagliptin (IC 50 = 14.8 n m ) (E), indicating differential inhibitor specificities within the DPPIV family. Each graph represents the mean data from triplicate experiments, and the error bars represent the standard deviation.
    H Met Gly Pro 7 Amino 4 Methylcoumarin Hydrochloride, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pro+fluorogenic+substrate/H-Met-Gly-Pro-AMC+Fluorogenic+Peptide+Substrate/pm24376907__ml400034m_si_001-17-4-15
    Average 94 stars, based on 1 article reviews
    h met gly pro 7 amino 4 methylcoumarin hydrochloride - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    R&D Systems methoxycoumarin 4 yl acetyl pro leu gly leu
    Enzyme activity profiles of DPPIV family proteases. (A) To compare the peptidase activities of hDPP4, hDPP9, C. elegans DPF‐3, and the catalytic mutant DPF‐3 (S784A), the <t>fluorogenic</t> <t>tripeptide</t> <t>substrate</t> <t>H‐Met‐Gly‐Pro‐AMC</t> was used over a range of concentrations (0.5–64 μ m ). hDPP4 displayed robust, concentration‐dependent activity, reaching 100% normalized fluorescence at 64 μ m substrate. In contrast, wild‐type DPF‐3 showed substantially lower activity, achieving only ~25% of the maximal signal at the highest substrate concentration. hDPP9 activity was negligible under these conditions, and the S784A mutation abrogated DPF‐3 activity completely, confirming loss of catalytic function. (B, C) Michaelis–Menten analysis of DPF‐3 (B) and hDPP4 (C) revealed distinct kinetic parameters. Nonlinear regression yielded for DPF‐3 a V max of 33 193 AU min −1 and a K m of 245.6 μ m . hDPP4 exhibited a higher catalytic efficiency, with V max = 56 027 AU min −1 and K m = 461.5 μ m . The higher V max of hDPP4, despite its higher K m , underscores its greater turnover capacity on this substrate. (D, E) Dose–response curves for the hDPP8/9 inhibitor 1G244 and the hDPP4 inhibitor vildagliptin were generated against DPF‐3 and hDPP4 using substrate concentrations near each enzyme's K m . For DPF‐3, 1G244 inhibited activity with an IC 50 = 499.5 n m , whereas vildagliptin was more potent (IC 50 = 142.1 n m ) (D). DPP4 was more sensitive to both 1G244 (IC 50 = 43.3 n m ) and vildagliptin (IC 50 = 14.8 n m ) (E), indicating differential inhibitor specificities within the DPPIV family. Each graph represents the mean data from triplicate experiments, and the error bars represent the standard deviation.
    Methoxycoumarin 4 Yl Acetyl Pro Leu Gly Leu, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pro+fluorogenic+substrate/Mca-PLGL-Dpa-AR-NH2+Fluorogenic+MMP+Substrate/us12421321-1652-22-26
    Average 93 stars, based on 1 article reviews
    methoxycoumarin 4 yl acetyl pro leu gly leu - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    97
    Thermo Fisher fluorogenic pop substrate suc gly pro leu gly pro 7 amido 4methylcoumarin amc
    Enzyme activity profiles of DPPIV family proteases. (A) To compare the peptidase activities of hDPP4, hDPP9, C. elegans DPF‐3, and the catalytic mutant DPF‐3 (S784A), the <t>fluorogenic</t> <t>tripeptide</t> <t>substrate</t> <t>H‐Met‐Gly‐Pro‐AMC</t> was used over a range of concentrations (0.5–64 μ m ). hDPP4 displayed robust, concentration‐dependent activity, reaching 100% normalized fluorescence at 64 μ m substrate. In contrast, wild‐type DPF‐3 showed substantially lower activity, achieving only ~25% of the maximal signal at the highest substrate concentration. hDPP9 activity was negligible under these conditions, and the S784A mutation abrogated DPF‐3 activity completely, confirming loss of catalytic function. (B, C) Michaelis–Menten analysis of DPF‐3 (B) and hDPP4 (C) revealed distinct kinetic parameters. Nonlinear regression yielded for DPF‐3 a V max of 33 193 AU min −1 and a K m of 245.6 μ m . hDPP4 exhibited a higher catalytic efficiency, with V max = 56 027 AU min −1 and K m = 461.5 μ m . The higher V max of hDPP4, despite its higher K m , underscores its greater turnover capacity on this substrate. (D, E) Dose–response curves for the hDPP8/9 inhibitor 1G244 and the hDPP4 inhibitor vildagliptin were generated against DPF‐3 and hDPP4 using substrate concentrations near each enzyme's K m . For DPF‐3, 1G244 inhibited activity with an IC 50 = 499.5 n m , whereas vildagliptin was more potent (IC 50 = 142.1 n m ) (D). DPP4 was more sensitive to both 1G244 (IC 50 = 43.3 n m ) and vildagliptin (IC 50 = 14.8 n m ) (E), indicating differential inhibitor specificities within the DPPIV family. Each graph represents the mean data from triplicate experiments, and the error bars represent the standard deviation.
    Fluorogenic Pop Substrate Suc Gly Pro Leu Gly Pro 7 Amido 4methylcoumarin Amc, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pro+fluorogenic+substrate/Leupeptin+hemisulfate/pm40764299-277-0-19
    Average 97 stars, based on 1 article reviews
    fluorogenic pop substrate suc gly pro leu gly pro 7 amido 4methylcoumarin amc - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    Image Search Results


    Enzyme activity profiles of DPPIV family proteases. (A) To compare the peptidase activities of hDPP4, hDPP9, C. elegans DPF‐3, and the catalytic mutant DPF‐3 (S784A), the fluorogenic tripeptide substrate H‐Met‐Gly‐Pro‐AMC was used over a range of concentrations (0.5–64 μ m ). hDPP4 displayed robust, concentration‐dependent activity, reaching 100% normalized fluorescence at 64 μ m substrate. In contrast, wild‐type DPF‐3 showed substantially lower activity, achieving only ~25% of the maximal signal at the highest substrate concentration. hDPP9 activity was negligible under these conditions, and the S784A mutation abrogated DPF‐3 activity completely, confirming loss of catalytic function. (B, C) Michaelis–Menten analysis of DPF‐3 (B) and hDPP4 (C) revealed distinct kinetic parameters. Nonlinear regression yielded for DPF‐3 a V max of 33 193 AU min −1 and a K m of 245.6 μ m . hDPP4 exhibited a higher catalytic efficiency, with V max = 56 027 AU min −1 and K m = 461.5 μ m . The higher V max of hDPP4, despite its higher K m , underscores its greater turnover capacity on this substrate. (D, E) Dose–response curves for the hDPP8/9 inhibitor 1G244 and the hDPP4 inhibitor vildagliptin were generated against DPF‐3 and hDPP4 using substrate concentrations near each enzyme's K m . For DPF‐3, 1G244 inhibited activity with an IC 50 = 499.5 n m , whereas vildagliptin was more potent (IC 50 = 142.1 n m ) (D). DPP4 was more sensitive to both 1G244 (IC 50 = 43.3 n m ) and vildagliptin (IC 50 = 14.8 n m ) (E), indicating differential inhibitor specificities within the DPPIV family. Each graph represents the mean data from triplicate experiments, and the error bars represent the standard deviation.

    Journal: Febs Letters

    Article Title: The Caenorhabditis elegans DPF ‐3 and human DPP4 have tripeptidyl peptidase activity

    doi: 10.1002/1873-3468.70219

    Figure Lengend Snippet: Enzyme activity profiles of DPPIV family proteases. (A) To compare the peptidase activities of hDPP4, hDPP9, C. elegans DPF‐3, and the catalytic mutant DPF‐3 (S784A), the fluorogenic tripeptide substrate H‐Met‐Gly‐Pro‐AMC was used over a range of concentrations (0.5–64 μ m ). hDPP4 displayed robust, concentration‐dependent activity, reaching 100% normalized fluorescence at 64 μ m substrate. In contrast, wild‐type DPF‐3 showed substantially lower activity, achieving only ~25% of the maximal signal at the highest substrate concentration. hDPP9 activity was negligible under these conditions, and the S784A mutation abrogated DPF‐3 activity completely, confirming loss of catalytic function. (B, C) Michaelis–Menten analysis of DPF‐3 (B) and hDPP4 (C) revealed distinct kinetic parameters. Nonlinear regression yielded for DPF‐3 a V max of 33 193 AU min −1 and a K m of 245.6 μ m . hDPP4 exhibited a higher catalytic efficiency, with V max = 56 027 AU min −1 and K m = 461.5 μ m . The higher V max of hDPP4, despite its higher K m , underscores its greater turnover capacity on this substrate. (D, E) Dose–response curves for the hDPP8/9 inhibitor 1G244 and the hDPP4 inhibitor vildagliptin were generated against DPF‐3 and hDPP4 using substrate concentrations near each enzyme's K m . For DPF‐3, 1G244 inhibited activity with an IC 50 = 499.5 n m , whereas vildagliptin was more potent (IC 50 = 142.1 n m ) (D). DPP4 was more sensitive to both 1G244 (IC 50 = 43.3 n m ) and vildagliptin (IC 50 = 14.8 n m ) (E), indicating differential inhibitor specificities within the DPPIV family. Each graph represents the mean data from triplicate experiments, and the error bars represent the standard deviation.

    Article Snippet: Enzymatic activities of hDPP4 and DPF‐3 were measured using the fluorogenic tripeptide substrate H‐Met‐Gly‐Pro‐AMC (7‐amino‐4‐methylcoumarin, Catalog number: ES017, R&D Systems).

    Techniques: Activity Assay, Mutagenesis, Concentration Assay, Fluorescence, Generated, Standard Deviation